Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR‐mutated lung adenocarcinoma who, after 23‐month treatment with gefitinib, developed the EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yutao, Hao, Xuezhi, Hu, Xingsheng, Li, Junling, Wang, Yan, Wang, Hongyu, Xing, Puyuan, Li, Weihua, Ying, Jianming, Han, Xiaohong, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879057/
https://www.ncbi.nlm.nih.gov/pubmed/29411527
http://dx.doi.org/10.1111/1759-7714.12596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879057/
https://www.ncbi.nlm.nih.gov/pubmed/29411527
http://dx.doi.org/10.1111/1759-7714.12596

Ejemplares similares